Drug intelligence / Profile preview

Bonafide-HF3.0

Development stage: Preclinical
Lead developer: Bonafide Health
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Bonafide-HF3.0 is a multi-ingredient dietary supplement developed by Bonafide Health for the management of vasomotor symptoms (VMS), such as hot flashes and night sweats, and other symptoms associated with menopause. The formulation contains green tea extract (GTE), curcumin, and phycocyanin derived from Spirulina (blue-green algae). It is designed as a non-hormonal alternative to hormone replacement therapy (HRT). The product is currently being evaluated in clinical trials to assess its efficacy in reducing the frequency and severity of menopausal symptoms in perimenopausal and postmenopausal women.

Brand names: Bonafide-HF3.0Bonafide-HF-3.0Bonafide-HF 3.0

Beyond the preview

Go deeper on Bonafide-HF3.0.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bonafide-HF3.0.

Explore the full profile